MorphoSys AG
Lena-Christ-Strasse 48
Martinsried
Munich
82152
Germany
Tel: 49-0-89-899-27-0
Fax: 49-0-89-899-27-222
Website: http://www.morphosys.com/
Email: info@morphosys.com
578 articles about MorphoSys AG
-
MorphoSys AG Signs Manufacturing Agreement with Boehringer Ingelheim Corporation
3/16/2011
-
MorphoSys AG to Present at Four Upcoming Investor Conferences
3/1/2011
-
MorphoSys AG Reports Results for Fiscal Year 2010
2/24/2011
-
MorphoSys AG Announces Change in Executive Management Board, CFO, Dave Lemus Steps Down
2/24/2011
-
MorphoSys AG Completes Technology Transfer in Strategic Antibody Alliance
2/22/2011
-
Invitation to Year End 2010 and Q4 Results Conference Call of MorphoSys AG on February 24, 2011
2/17/2011
-
MorphoSys AG Strengthens Patent Position on Lead Program MOR103
2/7/2011
-
MorphoSys AG to Present at Upcoming Investor Conference
2/2/2011
-
MorphoSys AG Reaches Clinical Milestone with Pfizer Inc.
1/31/2011
-
MorphoSys AG Reaches Clinical Milestone with OncoMed Pharmaceuticals, Inc.
1/31/2011
-
MorphoSys AG Announces Clinical Milestone within Boehringer Ingelheim Corporation Alliance
1/24/2011
-
MorphoSys AG Reports Preliminary, Unaudited Financial Results for 2010 and Provides First Outlook on 2011
1/21/2011
-
MorphoSys AG Announces Clinical Milestone from Strategic Alliance
1/12/2011
-
MorphoSys AG to Present at J.P. Morgan Healthcare Conference
1/5/2011
-
MorphoSys AG Reaches Seventh Clinical Milestone in 2010 from Centocor Ortho Biotech Inc.
12/22/2010
-
MorphoSys AG Signs Long-Term Alliance with Pfizer Inc. on Sloning Technology Platform
12/10/2010
-
MorphoSys AG Increases Revenues and Operating Profit Guidance for 2010
12/10/2010
-
MorphoSys AG Announces Three New Clinical Milestones
12/10/2010
-
Xencor and MorphoSys AG Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
12/2/2010
-
MorphoSys AG and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
12/2/2010